{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:51:14Z","timestamp":1793692274442,"version":"4.5.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T00:00:00Z","timestamp":1590192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T00:00:00Z","timestamp":1590192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The phase 3 ATLAS and FLAIR studies demonstrated that maintenance with Long-Acting (LA) intramuscular cabotegravir and rilpivirine is non-inferior in efficacy to current antiretroviral (CAR) oral therapy. Both studies utilized Patient-Reported Outcome instruments to measure treatment satisfaction (HIVTSQ) and acceptance (ACCEPT general domain), health status (SF-12), injection tolerability\/acceptance (PIN), and treatment preference. In pooled analyses, LA-treated patients (n\u2009=\u2009591) demonstrated greater mean improvements from baseline than the CAR group (n\u2009=\u2009591) in treatment satisfaction (Week 44,\u2009+ 3.9 vs.\u2009+0.5 HIVTSQs-points;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) and acceptance (Week 48,\u2009+8.8 vs.\u2009+2.0 ACCEPT-points;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). The acceptability of injection site reactions (PIN) significantly improved from week 5 (2.10 points) to week 48 (1.62 points;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). In both studies,\u2009\u2265\u200997% of LA group participants with recorded data preferred LA treatment compared with prior oral therapy. These results further support the potential of a monthly injectable option for people living with HIV seeking an alternative to daily oral treatment.\n                  <\/jats:p>","DOI":"10.1007\/s10461-020-02929-8","type":"journal-article","created":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T14:02:26Z","timestamp":1590242546000},"page":"3533-3544","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks"],"prefix":"10.1007","volume":"24","author":[{"given":"Miranda","family":"Murray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Antela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Lombaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Katner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Walmsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Aude","family":"Khuong-Josses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krischan","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dorey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Spreen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Vanveggel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Shaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Margolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3059-3324","authenticated-orcid":false,"given":"Vasiliki","family":"Chounta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,23]]},"reference":[{"issue":"Suppl 4","key":"2929_CR1","doi-asserted-by":"crossref","first-page":"18078","DOI":"10.7448\/IAS.15.6.18078","volume":"15","author":"M May","year":"2012","unstructured":"May M, Gompels M, Sabin C. Life expectancy of HIV-1-positive individuals approaches normal conditional on response to antiretroviral therapy: UK collaborative HIV cohort study. J Int AIDS Soc. 2012;15(Suppl 4):18078.","journal-title":"J Int AIDS Soc"},{"issue":"6122","key":"2929_CR2","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1126\/science.1230413","volume":"339","author":"J Bor","year":"2013","unstructured":"Bor J, Herbst AJ, Newell ML, Barnighausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science. 2013;339(6122):961\u20135.","journal-title":"Science"},{"issue":"7","key":"2929_CR3","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s10461-011-9942-x","volume":"15","author":"C Ortego","year":"2011","unstructured":"Ortego C, Huedo-Medina TB, Llorca J, et al. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav. 2011;15(7):1381\u201396.","journal-title":"AIDS Behav"},{"issue":"1","key":"2929_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/QAD.0b013e3282f366ff","volume":"22","author":"EM Gardner","year":"2008","unstructured":"Gardner EM, Sharma S, Peng G, et al. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS. 2008;22(1):75\u201382.","journal-title":"AIDS"},{"issue":"9","key":"2929_CR5","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1097\/00002030-200106150-00015","volume":"15","author":"DR Bangsberg","year":"2001","unstructured":"Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181\u20133.","journal-title":"AIDS"},{"issue":"2","key":"2929_CR6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/QAI.0000000000001896","volume":"80","author":"ED Weld","year":"2019","unstructured":"Weld ED, Rana MS, Dallas RH, et al. Interest of youth living with HIV in long-acting antiretrovirals. J Acquir Immune Defic Syndr. 2019;80(2):190\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"2929_CR7","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.2217\/nnm.12.214","volume":"8","author":"J Williams","year":"2013","unstructured":"Williams J, Sayles HR, Meza JL, et al. Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. Nanomedicine (Lond). 2013;8(11):1807\u201313.","journal-title":"Nanomedicine (Lond)"},{"key":"2929_CR8","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3389\/fphar.2017.00831","volume":"8","author":"SA Iacob","year":"2017","unstructured":"Iacob SA, Iacob DG, Jugulete G. Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful HIV treatment\u2013clinical points of view and practical considerations. Front Pharmacol. 2017;8:831.","journal-title":"Front Pharmacol"},{"issue":"8","key":"2929_CR9","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1080\/09540121.2019.1601676","volume":"31","author":"SK Been","year":"2019","unstructured":"Been SK, Schad\u00e9 A, Bassant N, Kastelijns M, Pog\u00e1ny K, Verbon A. Anxiety, depression and treatment adherence among HIV-infected migrants. AIDS Care. 2019;31(8):979\u201387.","journal-title":"AIDS Care"},{"issue":"4","key":"2929_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/COH.0000000000000168","volume":"10","author":"C Trezza","year":"2015","unstructured":"Trezza C, Ford SL, Spreen W, Pan R, Piscitelli S. Formulation and pharmacology of long-acting cabotegravir. Curr Opin HIV AIDS. 2015;10(4):239\u201345.","journal-title":"Curr Opin HIV AIDS"},{"key":"2929_CR11","unstructured":"Edurant (rilpivirine) prescribing information. 2018. Janssen Therapeutics. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/EDURANT-pi.pdf. Accessed March 25 2020."},{"issue":"12","key":"2929_CR12","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","volume":"382","author":"S Swindells","year":"2020","unstructured":"Swindells S, Andrade-Villanueva J-F, Richmond GJ, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382(12):1112\u201323.","journal-title":"N Engl J Med"},{"issue":"12","key":"2929_CR13","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","volume":"382","author":"C Orkin","year":"2020","unstructured":"Orkin C, Arasteh K, Hern\u00e1ndez-Mora MG, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020;382(12):1124\u201335.","journal-title":"N Engl J Med"},{"key":"2929_CR14","unstructured":"Overton E, Orkin C, Swindells S, et al. Monthly long-acting cabotegravir and rilpivirine is noninferior to oral ART as maintenance therapy for HIV-1 infection: Week 48 pooled analysis from the Phase 3 ATLAS and FLAIR studies. IAS Conference on HIV Science. Mexico City, Mexico, 2019 [poster MOPEB257]."},{"issue":"10101","key":"2929_CR15","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","volume":"390","author":"DA Margolis","year":"2017","unstructured":"Margolis DA, Gonzalez-Garcia J, Stellbrink H-J, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390(10101):1499\u2013510.","journal-title":"Lancet"},{"issue":"1","key":"2929_CR16","doi-asserted-by":"publisher","first-page":"e0190487","DOI":"10.1371\/journal.pone.0190487","volume":"13","author":"D Kerrigan","year":"2018","unstructured":"Kerrigan D, Mantsios A, Gorgolas M, et al. Experiences with long acting injectable ART: a qualitative study among PLHIV participating in a phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain. PLoS ONE. 2018;13(1):e0190487.","journal-title":"PLoS ONE"},{"issue":"6","key":"2929_CR17","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1023\/A:1013050904635","volume":"10","author":"A Woodcock","year":"2001","unstructured":"Woodcock A, Bradley C. Validation of the HIV treatment satisfaction questionnaire (HIVTSQ). Qual Life Res. 2001;10(6):517\u201331.","journal-title":"Qual Life Res"},{"issue":"5","key":"2929_CR18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1524-4733.2006.00121.x","volume":"9","author":"A Woodcock","year":"2006","unstructured":"Woodcock A, Bradley C. Validation of the revised 10-item HIV Treatment Satisfaction Questionnaire status version and new change version. Value Health. 2006;9(5):320\u201333.","journal-title":"Value Health"},{"issue":"7","key":"2929_CR19","doi-asserted-by":"publisher","first-page":"A420","DOI":"10.1016\/j.jval.2016.09.426","volume":"19","author":"J Romaine","year":"2016","unstructured":"Romaine J, Murray M, Bradley C. Psychometric evaluation of the revised HIV treatment satisfaction questionnaire (HIVTSQ). Value Health. 2016;19(7):A420.","journal-title":"Value Health"},{"key":"2929_CR20","doi-asserted-by":"crossref","unstructured":"Romaine J, Murray M, Bradley C. Investigating the responsiveness to change of the HIV Treatment Satisfaction Questionnaire change version (HIVTSQc) in overcoming ceiling effects in the HIV Treatment Satisfaction Questionnaire status version (HIVTSQs). ISPOR Europe. Copenhagen, Denmark, 2019 [abstract PIH62].","DOI":"10.1016\/j.jval.2019.09.1242"},{"key":"2929_CR21","unstructured":"Murray M, Dorey D, Griffith S, et al. Satisfaction, tolerability, and acceptability of cabotegravir (CAB) + rilpivirine (RPV) long-acting therapy: LATTE-2 results. International AIDS Conference. Durban, South Africa, 2016 [poster THPEB052]."},{"issue":"4","key":"2929_CR22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF03262496","volume":"5","author":"C Marant","year":"2012","unstructured":"Marant C, Longin J, Gauchoux R, et al. Long-term treatment acceptance: what is it, and how can it be assessed? Patient. 2012;5(4):239\u201349.","journal-title":"Patient"},{"issue":"1","key":"2929_CR23","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12955-018-0962-3","volume":"16","author":"J Lambert","year":"2018","unstructured":"Lambert J, Chekroun M, Gilet H, Acquadro C, Arnould B. Assessing patients' acceptance of their medication to reveal unmet needs: results from a large multi-diseases study using a patient online community. Health Qual Life Outcomes. 2018;16(1):134.","journal-title":"Health Qual Life Outcomes"},{"key":"2929_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1477-7525-7-21","volume":"7","author":"C Chevat","year":"2009","unstructured":"Chevat C, Viala-Danten M, Dias-Barbosa C, Nguyen VH. Development and psychometric validation of a self-administered questionnaire assessing the acceptance of influenza vaccination: the Vaccinees' Perception of Injection (VAPI) questionnaire. Health Qual Life Outcomes. 2009;7:21.","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"2929_CR25","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","volume":"34","author":"J Ware Jr","year":"1996","unstructured":"Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220\u201333.","journal-title":"Med Care"},{"issue":"9","key":"2929_CR26","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.puhe.2009.07.013","volume":"123","author":"I Failde","year":"2009","unstructured":"Failde I, Medina P, Ram\u00edrez C, Arana R. Assessing health-related quality of life among coronary patients: SF-36 vs SF-12. Public Health. 2009;123(9):615\u20137.","journal-title":"Public Health"},{"issue":"8","key":"2929_CR27","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1007\/s00167-015-3904-1","volume":"24","author":"KE Webster","year":"2016","unstructured":"Webster KE, Feller JA. Comparison of the short form-12 (SF-12) health status questionnaire with the SF-36 in patients with knee osteoarthritis who have replacement surgery. Knee Surg Sports Traumatol Arthrosc. 2016;24(8):2620\u20136.","journal-title":"Knee Surg Sports Traumatol Arthrosc"},{"issue":"4","key":"2929_CR28","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1053\/j.jfas.2015.12.009","volume":"55","author":"DK Wukich","year":"2016","unstructured":"Wukich DK, Sambenedetto TL, Mota NM, Suder NC, Rosario BL. Correlation of SF-36 and SF-12 component scores in patients with diabetic foot disease. J Foot Ankle Surg. 2016;55(4):693\u20136.","journal-title":"J Foot Ankle Surg"},{"issue":"6","key":"2929_CR29","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473\u201383.","journal-title":"Med Care."},{"issue":"1","key":"2929_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12955-018-0858-2","volume":"16","author":"T Huo","year":"2018","unstructured":"Huo T, Guo Y, Shenkman E, Muller K. Assessing the reliability of the Short Form 12 (SF-12) Health survey in adults with mental health conditions: a report from the wellness incentive and navigation (WIN) study. Health Qual Life Outcomes. 2018;16(1):34.","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"2929_CR31","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3171\/jns.2005.102.3.0489","volume":"102","author":"JT King Jr","year":"2005","unstructured":"King JT Jr, Horowitz MB, Kassam AB, Yonas H, Roberts MS. The short form-12 and the measurement of health status in patients with cerebral aneurysms: performance, validity, and reliability. J Neurosurg. 2005;102(3):489\u201394.","journal-title":"J Neurosurg"},{"issue":"1","key":"2929_CR32","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13075-015-0658-6","volume":"17","author":"SK Rai","year":"2015","unstructured":"Rai SK, Yazdany J, Fortin PR, Avi\u00f1a-Zubieta JA. Approaches for estimating minimal clinically important differences in systemic lupus erythematosus. Arthritis Res Ther. 2015;17(1):143.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2929_CR33","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12955-018-1055-z","volume":"16","author":"A Ousmen","year":"2018","unstructured":"Ousmen A, Touraine C, Deliu N, et al. Distribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured review. Health Qual Life Outcomes. 2018;16(1):228.","journal-title":"Health Qual Life Outcomes"},{"key":"2929_CR34","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.msard.2019.01.044","volume":"30","author":"L Mayer","year":"2019","unstructured":"Mayer L, Kappos L, Racke MK, et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord. 2019;30:236\u201343.","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"2929_CR35","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ana.21867","volume":"66","author":"K Hawker","year":"2009","unstructured":"Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66(4):460\u201371.","journal-title":"Ann Neurol"},{"issue":"7","key":"2929_CR36","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1212\/WNL.0000000000000125","volume":"82","author":"PS Sorensen","year":"2014","unstructured":"Sorensen PS, Lisby S, Grove R, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology. 2014;82(7):573\u201381.","journal-title":"Neurology"},{"issue":"7","key":"2929_CR37","doi-asserted-by":"publisher","first-page":"pyw018","DOI":"10.1093\/ijnp\/pyw018","volume":"19","author":"AJ Savitz","year":"2016","unstructured":"Savitz AJ, Xu H, Gopal S, et al. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study. Int J Neuropsychopharmacol. 2016;19(7):pyw018.","journal-title":"Int J Neuropsychopharmacol."},{"key":"2929_CR38","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.2147\/PPA.S141762","volume":"11","author":"J Boretzki","year":"2017","unstructured":"Boretzki J, Wolf E, Wiese C, et al. Highly specific reasons for nonadherence to antiretroviral therapy: results from the German adherence study. Patient Prefer Adherence. 2017;11:1897\u2013906.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"2929_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1089\/apc.2005.19.9","volume":"19","author":"J Jordan","year":"2005","unstructured":"Jordan J, Cahn P, Goebel F, Matheron S, Bradley C, Woodcock A. Abacavir compared to protease inhibitors as part of HAART regimens for treatment of HIV infection: patient satisfaction and implications for adherence. AIDS Patient Care STDs. 2005;19(1):9\u201318.","journal-title":"AIDS Patient Care STDs"},{"key":"2929_CR40","doi-asserted-by":"crossref","unstructured":"Delestras S, Roustit M, Mazet R, et al. Patient satisfaction with medication as an outcome for clinical pharmacists. Presented at 39th ESCP European symposium on clinical pharmacy & 13th SFPC congress: clinical pharmacy at the front line of innovations. 21\u201323 October 2010, Lyon, France. Int J Clin Pharm. 2011;33:285\u2013467.","DOI":"10.1007\/s11096-011-9481-6"},{"issue":"Suppl 2","key":"2929_CR41","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1093\/ofid\/ofz359.043","volume":"6","author":"P Teichner","year":"2019","unstructured":"Teichner P, Cutrell A, D\u2019Amico R, et al. Patient adherence to long-acting injectable cabotegravir + rilpivirine through 48 weeks of maintenance therapy in the Phase 3 ATLAS and FLAIR studies. Open Forum Infect Dis. 2019;6(Suppl 2):S20.","journal-title":"Open Forum Infect Dis"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-020-02929-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-020-02929-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-020-02929-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T08:00:08Z","timestamp":1696147208000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-020-02929-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,23]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2929"],"URL":"https:\/\/doi.org\/10.1007\/s10461-020-02929-8","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,23]]},"assertion":[{"value":"23 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Vasiliki Chounta, Krischan Hudson, Sandy Griffith, William Spreen, Mark Shaefer and David Margolis are employees of ViiV Healthcare and own company stocks of GlaxoSmithKline (GSK). Jenny Huang and David Dorey are employees of GSK and own company stocks of GSK. Anthony Mills has received honoraria for consulting for the following companies: Merck, ViiV Healthcare, Janssen, and Gilead Sciences. The Men\u2019s Health Foundation receives research support for clinical trials for which Anthony Mills is an investigator. Hans J\u00e4ger has received lecture sponsorship or has served on advisory boards for the following companies: AbbVie, Gilead, GSK, Janssen, MSD Sharp & Dohme, TAD and ViiV Healthcare. Sharon Walmsley has served on advisory boards, speaking engagements, meetings, symposiums, and clinical studies for the following companies: ViiV Healthcare, GSK, Merck, Janssen, and Gilead Sciences. Simon Vanveggel is an employee and shareholder of Janssen, Pharmaceutical Companies of Johnson & Johnson. All other authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of a national, regional, or investigational center ethics committee, or institutional review board, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}